Gastrointestinal and Hematologic Adverse Events after Administration of Vincristine, Cyclophosphamide, and Doxorubicin in Dogs with Lymphoma that Underwent a Combination Multidrug Chemotherapy Protocol

Abstract

ABSTRACT. The present study aimed to objectively evaluate the adverse events after the administration of chemotherapeutic agents used in the University of Wisconsin (UW)-Madison chemotherapy protocol (UW-25) for canine lymphoma, using the Veterinary Co-operative Oncology Group common terminology criteria for adverse events (VCOG-CTCAE). The medical records of 40 dogs with multicentric high-grade lymphoma that underwent UW-25 were reviewed. Gastrointestinal adverse events of grade 2 and above and blood/bone marrow adverse events of all grades were evaluated. Gastrointestinal adverse events occurring at least once during the entire period of UW-25 were observed in 50% (20/40), 17.9% (7/39), and 8.1% (3/37) of the dogs after the administration of vincristine (VCR), cyclophosphamide (CPA), and doxorubicin (DXR), respectively. Blood/bone marrow adverse events occurring at least once during UW-25 were observed in 57.5% (23/40), 41% (16/39), and 8.1% (3/37) of the dogs after the administration of VCR, CPA, and DXR, respectively. The rate of patients that experienced gastrointestinal adverse events was higher after the first administration of VCR than after the first administration of DXR. Findings obtained in this study will be helpful in predicting the adverse events that could occur when dogs with lymphoma are treated with UW-25.

Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy

“…Although the percentage of dogs that experienced hospitalization (34%) in our study was higher than in previous reports (9.8–11.5%), the overall incidence of hospitalization was 5%, as previously reported . Upon evaluation of VCOG toxicity scores, actual scores were similar to those previously reported . The relatively higher rate of hospitalization may have resulted from the fact that there is subjectivity about the need for hospitalization, which may relate to the clinician who evaluated the case, comfort level of the client, or both.…”

Empleo del Sulfato de Vincristina, Vía Subcutánea, para el Control del Tumor Venéreo Transmisible Canino: Estudio Retrospectivo de Siete Casos en Camagüey, Cuba

“…La vincristina tiene un efecto mielosupresor leve (Plumb, 2006) y efectos secundarios como anorexia, vómito, diarrea y neutropenia (Tomiyasu et al, 2011); sin embargo, solo se evidenció anorexia en un caso, aunque de corta duración.…”

Respuesta del Tumor Venéreo Transmisible Canino a Presentaciones de Vincristina de Patente y Genérica

“…La vincristina tiene un efecto mielosupresor leve (Plum, 2006) y efectos secundarios como anorexia, vómito, diarrea y neutropenia (Tomiyasu et al, 2011). Sin embargo, pese a los problemas digestivos y mielosupresión observados en el presente estudio, estas manifestaciones no fueron de gran relevancia ya que los pacientes nunca presentaron una merma en su condición corporal durante el tratamiento.…”

“…El tratamiento con sulfato de vincristina en dosis semanal de 0.025 mg/kg tiene buenos resultados y los efectos colaterales como vómito, diarrea, anorexia y neutropenia son mínimos (Vermooten, 1987). Habitualmente se utiliza una presentación comercial que contiene 1.0 mg de sulfato de vincristina, pudién-dose requerir entre 4 y 7 aplicaciones, conforme a la evolución del paciente (Brown et al, 1980;Tomiyasu et al, 2011). No obstante, se ha demostrado que la vincristina causa alteraciones gastrointestinales, aún más que la doxorrubicina, en el perro (Tomiyasu et al, 2011).…”

“…Habitualmente se utiliza una presentación comercial que contiene 1.0 mg de sulfato de vincristina, pudién-dose requerir entre 4 y 7 aplicaciones, conforme a la evolución del paciente (Brown et al, 1980;Tomiyasu et al, 2011). No obstante, se ha demostrado que la vincristina causa alteraciones gastrointestinales, aún más que la doxorrubicina, en el perro (Tomiyasu et al, 2011). De hecho, la aplicación de vincristina incrementa el riesgo de desarrollo de sepsis cuando se administran más de nueve dosis (Sorenmo et al, 2010).…”